LamotriginevDispersible tablets

LamotriginevDispersible tablets

Form: Tablets(IR & ER)

Strength: XR: 25 mg, 50 mg, 100 mg, 200 mg; IR: 25 mg, 100 mg, 200 mg, 300 mg

Reference Brands: Lamictal, Lamictal XR(EU & US)

Category: Multiple sclerosis

Lamotrigine dispersible tablets, available as immediate-release (IR) and extended-release (ER), are approved in the US by the FDA and in the EU via EMA for epilepsy and bipolar disorder management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial data and manufacturing processes, while the EMA ensures compliance with regional safety and quality regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance facilitates timely approvals, supports safe use, and promotes worldwide availability of lamotrigine dispersible tablets, improving long-term patient care globally.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Tolterodine tablets/ Capsules(IR & ER)

Strength: IR: 1 mg, 2 mg; ER: 2mg, 4 mg

Form: Tablets/ Capsules(IR & ER)

Reference Brands: Detrol, Detrol LA(US & EU)

View Details Get Enquiry
Oxybutynin tstransdermal patch

Strength: 3.9 mg/24 hours

Form: transdermal patch

Reference Brands: Oxytrol, Oxytrol for Women(US & EU)

View Details Get Enquiry
Oxybutynin tablets

Strength: IR: 5 mg, 10 mg; ER: 5 mg, 10 mg

Form: Tablet(IR & ER)

Reference Brands: Ditropan, Oxybutynin XL(US)

View Details Get Enquiry
Dalfampridine

Strength: 10 mg

Form: Extended-Release tablets (XR)

Reference Brands: Ampyra(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.